Mean platelet volume (MPV) and platelet count (PLT) are platelet measures that have been linked to cardiovascular disease (CVD) and mortality risk. Identifying protein biomarkers for these measures may yield insights into CVD mechanisms.
Introduction
Platelets are circulating anucleate cells produced by megakaryocytes (MK) in the bone marrow 1 that initiate thrombus formation at the site of injury 2 . They also function as innate and adaptive immunity regulators through secretion of antibacterial proteins, interactions with leukocytes, and mediation of proinflammatory functions of neutrophils and dendritic cells 3 . Their central roles in thrombus formation and immune response make platelets notable contributors to the pathobiology of atherosclerosis 4 and arterial and venous thrombosis 5 , including venous thromboembolism (VTE) 6 . When the endothelium of a vessel is damaged, platelets aggregate at the site of injury and can promote atherosclerosis and atherothrombosis 5 , which in turn can cause acute coronary syndromes and strokes 7 . A widely-used platelet clinical metric, mean platelet volume (MPV) 8 , has been reported to be associated with risk of acute myocardial infarction (AMI) events 9 , coronary artery disease (CAD) 10 , and VTE 6 . Prior studies have also shown that higher MPV is associated with greater mortality risk among AMI patients 9 and patients with sepsis 11 . Furthermore, greater MPV is also correlated with poor prognosis for patients with infective endocarditis 12 and risk of pulmonary embolism among patients with deep vein thrombosis 13 . A prospective cohort study by Mayer and colleagues demonstrated that elevated MPV levels were associated with increased risk of major adverse cardiovascular events among patients with asymptomatic carotid atherosclerosis 14 . Platelet count (PLT), on the other hand, has a U-shaped association with mortality; high-and low-platelet counts have been reported to be associated with increased risk of coronary heart disease (CHD) and cancer mortality 15 and with overall mortality in people older than 65 years of age 16, 17 .Therefore, given the clinical importance of platelets vis-à-vis cardiovascular diseases (CVD), identifying putatively causal protein biomarkers associated with MPV and PLT may lead to a better understanding of disease mechanisms and highlight therapeutic targets for the treatment and prevention of CVD.
As part of the Systems Approach to Biomarker Research in Cardiovascular Disease (SABRe CVD) Initiative, we conducted a genome-wide association study (GWAS) to identify genetic loci associated with circulating levels of 71 CVD-related plasma proteins (pQTLs; protein quantitative trait loci) in 7333 Framingham Heart Study (FHS) participants 18 . In the present study we sought to identify associations between circulating protein levels and platelet phenotypes.
Identifying overlap between genetic variants associated with circulating protein levels and single nucleotide polymorphisms (SNPs) associated with complex traits from previously published genomewide association studies (GWAS) can prioritize candidate protein biomarkers that can be further explored as causal proteins for disease and/or drug targets of complex disease phenotypes. We previously demonstrated the utility of this technique by identifying putatively causal protein biomarkers for CVD 18 and chronic obstructive pulmonary disease 19 . Because PLT and MPV are highly heritable quantitative traits 20 with large published GWAS and exome studies [21] [22] [23] , we hypothesized that these traits may be amenable to a similar approach to identify causal protein biomarkers. To that end, we conducted Mendelian randomization (MR) analyses to test for putatively causal associations between protein biomarkers and MPV and PLT. Proteins that were associated with MPV or PLT in both FHS data and MR were functionally validated using RNA-sequencing data of human induced pluripotent stem cells (iPSC) MK clones followed by siRNA gene knockdown experiments.
Methods
Study Design: An overall flowchart of our study design is shown in Figure 1 . We first conducted proteintrait association analyses using FHS data 24 for MPV and PLT. We then performed MR using cis-pQTL variants 18 that overlapped with prior MPV/ PLT GWAS 21, 22 SNPs as instrumental variables to test for putatively causal protein-MPV/PLT associations. Proteins showing significant causal association were further investigated for transcriptome-level association with platelet production using RNA sequencing data from human iPSC MK. Finally, we performed gene knockdown experiments in iPSC MK.
Protein-Trait Association Analysis
Study participants: The study sample consisted of FHS Offspring and Third Generation cohort participants. The FHS Offspring study was comprised of 5124 children or spouses of original FHS cohort participants; enrollment began in 1971 25, 26 Protein quantification: All plasma proteins were measured as part of the Systems Approach to Biomarker Research in Cardiovascular Disease (SABRe CVD) Initiative 24 . The protein quantification procedure has been described previously 18 . Briefly, fasting blood plasma samples were analyzed using a modified enzyme-linked immunosorbent assay sandwich method, multiplexed on Luminex xMAP platform (Luminex, Inc., Austin, TX), for plasma protein levels 18 .
Statistical methods: We applied linear mixed effects models (LME) to characterize significant associations between 71 plasma proteins and platelet measurements (MPV and PLT). We adjusted for sex, age at the time of platelet measurement, age squared, and ten genotype-based principal components, and derived the residuals. The residuals were inverse normalized and tested for association with the 71 plasma proteins using LME. Bonferroni corrected significance threshold was used to identify significant biomarkers associated with platelet measurements.
Causal genetic polymorphisms
Identifying overlap of pQTL variants with GWAS variants: We interrogated our pQTL database 18 (n=6861 participants were included in the GWAS sample with 1000 Genomes Project reference panel (1000G build 37 phase 1 v3) imputed dosage data) for overlap of cis-pQTL and trans-pQTL variants with single nucleotide polymorphisms (SNPs) from prior genome-wide association studies (GWAS) of MPV and PLT 21, 22 . Only cis-pQTLs that passed Bonferroni-corrected (BF) significance threshold at P < 1.25E-07 and trans-pQTLs that passed BF significance threshold at P < 7.04E-10 were considered for overlap analysis 18 .
MR testing for causal protein-trait association: MR was conducted using the TwoSampleMR 28 R package using pruned cis-pQTL variants ( linkage disequilibrium [LD] threshold of r 2 < 0.1) as instrumental variables. Among the 71 CVD-related proteins, 37 proteins had cis-pQTL variants that were suitable as instrumental variables in MR. The Wald ratio, which is a ratio of the regression coefficient of the exposure on the instrumental variable to that of the outcome on the instrumental variable 29 , was used for proteins with one independent cis-pQTL, and inverse-variance weighted regression was used for proteins with multiple independent cis-pQTL variants 30 . Differentiation of imMKCLs to generate platelets: Induction of imMKCL maturation was carried out in a humidified incubator at 37C and 5% CO2 with for 6 days in IMDM medium supplemented with 15% FBS consisted of 50 ng/mL SCF, 50 ng/mL TPO, 15 mM KP-457 (Medchemexpress), 0.5 mM GNF-351 (TOCRIS), and 10 mM Y27632 (Medchemexpress). On day 3 imMKCLs are highly polyploid and poised for platelet generation and platelet generation occurs between day 5 and 6.
RNA sequencing analysis
Since heterogenous (Het) imMKCLs consisted of both non-platelet producing and platelet producing megakaryocytes, the imMKCLs were subcloned to decrease the ratio of non-platelet producing and platelet producing megakaryocytes. Subcloning of imMKCLs resulted in derivation of functionally distinct subclones. The 7 subclones varied in their ability to generate platelets and were labeled as Clone 
siRNA gene knockdown experiments
Immortalized megakaryocyte progenitor cell lines (imMKCL) culture: imMKCLs were generated from human induced pluripotent stem cells (iPSCs) and maintained in presence of 5 μg/mL doxycycline (DOX) as previously described 31 . Removal of DOX results in imMKCL maturation and the generation of platelets after six days. siRNA transfection assay: The imMKCLs growing in the differentiation medium (without DOX) on day 4
were seeded in a 24-well plate, 24 hours prior to transfection. The cells were transfected with 2ug esiRNA (mixture of siRNA oligos, (Sigma-aldrich)) specific to MCAM, MPO and GRN as well as 500nM of siRNA targeted against GP5 or control eGFP siRNA oligonucleotides using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's instructions. 48 hours post-transfection, the cells were harvested for RT-qPCR and in vitro flow cytometric analysis of platelets.
RNA extraction, reverse transcription, and RT-qPCR: RNA extraction was performed using an RNAeasy kit (Qiagen). Reverse transcription was performed using Superscript III (Invitrogen), using Oligo (dT) 15 primer. Quantitative PCR was performed in triplicate with SYBR Green and CFX96 real-time PCR detection system (Bio-rad). Target transcript abundance was calculated relative to GAPDH (reference gene) using the 2-ΔΔCT method. Gene specific primer pairs are present in Supplementary Table 1 . 
Results

FHS protein-MPV/PLT association analyses
Among the 71 CVD-related plasma proteins, ten (14.1%) were associated with MPV after Bonferroni (BF) correction (P < 0.05/71) and another 17 (23.9%) proteins were nominally significant (P < 0.05). For PLT, 31 (43.7%) proteins showed significant association after BF correction and 13 (18.3%) were nominally significant (P < 0.05) ( Table 2 and Supplementary Table 2 ). Seven proteins showed significant association with both PLT and MPV: soluble CD40 ligand (sCD40L), stromal cell-derived factor 1 (SDF1), pro-platelet basic protein (PPBP), translocation associated notch homolog (Notch1), adrenomedullin (ADM), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and cadherin-13 (CDH13). All seven proteins' direction of effect for MPV was the opposite of their direction of effect for PLT (Pearson's correlation: -0.90, 95% CI: (-0.99, -0.48)), reflecting the inverse correlation of MPV and PLT 32 .
pQTL variants that overlap with published GWAS of MPV and PLT
We identified 15 pQTLs (four cis-and 11 trans-pQTLs) corresponding to 15 proteins that overlapped with MPV-GWAS SNPs ( Table 3) . Among the 15 proteins, CDH13 was significantly associated with MPV in FHS data after BF correction ( Table 2) , and six proteins (sRAGE, PMP2, LDLR, ADAM15, CD14, and NRCAM) showed nominal significance. Seventeen pQTLS (five cis-and 12 trans-pQTLs) corresponding to 17 proteins overlapped with PLT-GWAS SNPs ( Table 4 ). Among these 17 proteins, 12 proteins (GMP140, sRAGE, GP5, CDH13, LDLR, NRCAM, PMP2, KLKB1, ADAM15, ANGPTL3, C2, MCAM) passed BF correction threshold and were associated with PLT in FHS data ( Table 2) , and two proteins (CD14, GRN) showed nominal significance.
MR analyses
We conducted MR analyses using 40 proteins with cis-pQTL variants. Three of the 40 proteins did not have pQTLs that overlapped with GWAS variants for MPV/PLT. Thus, 37 proteins were tested for putatively causal associations with MPV/PLT. MR analysis revealed four proteins that were causally associated with MPV after BF correction (P < 0.05/37) and five proteins that were nominally significant at P < 0.05 ( Table 5 and Supplementary Table 3 ). Similarly, four proteins were causally associated with PLT after BF correction and five showed nominally significant association ( Table 5 and Supplementary   Table 3 ). SERPINA10 was tested for horizontal pleiotropy and heterogeneity because it had 28 SNPs (Supplementary Table 4) ; there was no evidence of horizontal pleiotropy (Egger regression intercept: 0.005, p-value: 0.14), but a forest plot of individual SNP MR effect size and a test based on the Egger method confirmed heterogeneity (p-value: 0.022) ( Supplementary Figure 1-2) . Removal of seven SERPINA10 cis-pQTL SNPs with negative MR coefficients resulted in modest improvement of the effect size and significance (IVW MR β: 0.019, SE: 0.0036, p-value: 1.69E-07) (Supplementary Figure 3) .
Granulin (GRN) and platelet glycoprotein V (GP5) were causally associated with both MPV and PLT ( Table 5) .
Myeloperoxidase (MPO) was positively associated with MPV in both MR and protein-trait association analyses after BF correction, with directional consistency of effect estimates between the two analyses (Figure 2) . N-terminal prohormone of brain natriuretic peptide (NTproBNP) was nominally significant in both analyses with directional consistency (Figure 2) . Melanoma cell adhesion molecule (MCAM/CD146/MUC18) and glycoprotein V (GP5) were associated with PLT in both MR and proteintrait association analyses with directional consistency (Figure 2) . GRN was BF significant in MR but nominally significant in protein-PLT analysis with directional consistency. Adrenomedullin (ADM), contactin 1 (CNTN1), and C-reactive protein (CRP) were BF significant in protein-PLT association analysis but nominally significant in MR; ADM showed directionally consistent effect estimates, but CNTN1 and CRP showed directional inconsistency (Figure 2) . Instrumental variable SNPs for GP5, GRN, MCAM, and MPO (Supplementary Table 4) , the genes carried forward in experiments, were queried for CHD outcome associations in CARDIoGRAMplusC4D 33 , UK BioBank GWAS 34 , the MEGASTROKE Consortium 35 , and the Japan BioBank 36 ( Supplementary Table 5 ).
RNA sequence analysis of iPSC MK
To validate our findings from protein-trait association and MR analyses, we utilized human iPSCderived MK clones that produced variable numbers of functional platelets to conduct a MK RNAsequencing and analyzed transcriptome-wide differences between low-and high-platelet producing clones. The transcription levels of PLT-associated proteins in the iPSC MK clones showed directionally consistent associations with platelet productivity that we expected based on our human population genetics analyses (Table 6, Supplementary Figure 4-6) .
siRNA gene knockdown experiments using iPSC MK
Motivated by our findings from the RNA sequencing analysis, we performed a siRNA gene knockdown experiment using the iPSC MK clones. Silencing GRN, GP5, and MPO genes in MK clones caused substantial reductions in platelet production (Figure 3, Supplementary Table 6, Supplementary Figure   7 ). Knockdown of MCAM appears to potentially increase platelet production, but the difference in platelet counts of MCAM knockdown and that of the control (GFP) group was not statistically significant.
The gene knockdown experiments provide further support for causal association between GP5 and GRN and PLT. In addition, the experiments indicate that MPO may also be causally associated with PLT.
Discussion
There have been several large genetic studies of PLT and MPV, epidemiological studies of clinical correlates of PLT and MPV 21, 22 , and studies of plasma pQTLs 24, 37, 38 . To our knowledge, this is the first study to integrate plasma protein measurements, pQTL associations, and genetic studies using MR to identify putatively causal biomarkers of PLT and MPV followed by iPSC MK clone gene silencing experiments.
Three proteins (GP5, GRN, MCAM) were associated with PLT in FHS protein-trait, MR, as well as iPSC MK clone gene expression analyses ( Table 2 , 5, and 6). The causal roles of GP5 and GRN on PLT were further supported by iPSC MK gene knockdown experiments (Figure 3) . GP5 is a transmembrane glycoprotein expressed on the surface of platelets. It has a soluble extracellular domain, which is cleaved by thrombin during thrombin-induced platelet activation 39 . Mutations in GP5 are not known to cause Bernard-Soulier syndrome (enlarged platelets associated with bleeding and thrombocytopenia) unlike other gene members of the GPIb-V-IX complex. However, prior and recent work has suggested that alloantibodies targeting GP5 40 , as well as pediatric varicella 41 , gold-triggered autoimmune responses in rheumatoid arthritis 42 , and quinidine-related platelet directed antibodies 43 may trigger immune thrombocytopenia via GP5. These studies suggest that GP5 alterations may trigger platelet clearance, and that maintenance of normal GP5 function or high levels on platelets could preserve platelet numbers in circulation. We observed consistent association between higher levels of plasma GP5 and PLT in our analyses. When we knocked down GP5 in the iPSC MK system, we observed reduced platelet production. Of note, a trans-pQTL SNP (rs7116008) that showed the most significant association with PLT among GP5 pQTLs ( Table 4 ) is an intronic variant in gene ST3GAL4, which encodes the ST3GAL4 enzyme that is responsible for sialyation of lectin asialoglycoprotein receptor (ASGPR;
Ashwell-Morell Receptor (AMR)) ligand on platelets 44 . Sialic-acid deficient platelets of ST3GAL4 knockout mice were cleared from circulation faster than platelets of wild type mice 44 . Therefore, positive correlation between GP5 and PLT might be explained by a direct effect on platelet production and an indirect effect through platelet clearance mediated by ST3GAL4 desialyation of GP5 associated with its trans-pQTL 44, 45 .
Granulin (GRN/epithelin) is a family of seven protein growth factors with homologous structures 46, 47 . Granulin's precursor, progranulin (PGRN), consists of a paragranulin domain and seven GRN domains that can be cleaved and released by proteases including MMP9, MMP12, and ADAMTS-7 48 . PGRN and GRN have opposite effects on cells; GRN B promotes secretion of interleukin 8 (IL-8) by epithelial cells, but PGRN does not cause such response 46 . IL-8 has been shown to hyper-activate platelets and induce procoagulant behavior 49 . The opposing effects of GRN/PGRN on IL-8 release was also observed in human aortic smooth muscle cells 50 . PGRN appears to be anti-inflammatory 50, 51 while GRN shows pro-inflammatory behavior 46 . PGRN has previously been implicated in blood lipid effects on CVD through its connection to sortilin (SORT1). Sortilin binds to PGRN and is responsible for endocytosis and transportation of PGRN to lysosomes 52 . A strong trans-pQTL for PGRN (rs646776), located on chromosome 1p13, was associated with CELSR2 (cadherin EGF LAG seven-pass G-type receptor 2), PSRC1 and SORT1 (sortilin) mRNA expression 53 . SNP rs646776 was also associated with blood lowdensity lipoprotein (LDL) cholesterol levels and myocardial infarction risk 54 . GRN was associated with an increased risk of CVD death in a previous study 18 . Our MR analysis results using two cis-pQTLs of GRN (rs35203463, rs850733) and the siRNA experiment showed that silencing GRN expression leads to a decreased platelet count, suggesting a novel pathway linking GRN and CVD through platelet effects.
MPO is a heme-enzyme and a bactericidal protein found in neutrophils, specifically in azurophilic granules 55 . In addition to its role in immune response to pathogens, MPO has been suggested to play a role in inflammatory conditions and CVD 55 . MPO shows nominally significant, positive associations with coronary heart disease (CHD) events risk and CVD death in FHS data, and a positive association with CHD risk in MR 18 . In queries of publicly available GWAS data, we found consistent associations of MPO increasing alleles with CHD outcomes (Supplementary Table 5 ). MPO partially activates platelets, increasing platelets' surface expression of P-selectin and PECAM-1 receptors as well as the frequency of aggregate formation with neutrophil granulocytes 56 . In our study, MPO was positively associated with MPV in both FHS protein-trait and MR analyses after correction for multiple testing (Table 2 and 5) .
MPO also showed a positive, nominally significant (P = 0.03), association with PLT in FHS data ( Supplementary Table 2 ); furthermore, MPO knockdown MK clones showed a statistically significant decrease in MK derived platelet count, demonstrating a positive correlation between the protein and platelet production (Figure 3) . MPO's positive correlation with both MPV and PLT is not concordant with the inverse relationship between MPV and PLT shown in prior literature 32 MCAM was negatively correlated with CHD risk in a prior MR study 18 . The MCAM instrumental variable SNP (rs11217234) in our study was nominally associated with (P = 0.027) with decreased risk of a second myocardial infarction event ( Supplementary Table 5 ). MCAM is an important contributor to development of atherosclerosis; however, its relationship to PLT or MPV has not been studied extensively. In our study, MCAM was causally associated with decreased PLT in MR, but this inferred causality was not supported by iPSC MK gene silencing experiment (Figure 3) .
Our study has several limitations. The first limitation is the time gap between plasma protein and platelet measurements in FHS participants. FHS Offspring cohort participants' protein measurement (Exam 7) and platelet measurement (Exam 9) were about 13 years apart and FHS Third Generation cohort participants' protein measurement (Exam 1) and platelet measurement (Exam 2) were 6 years apart.
These time differences can weaken the association between protein levels and platelet traits. Second, FHS Offspring and Third Generation cohorts consist of people of European descent, potentially limiting the generalizability of study findings. The third limitation is that the proteins measured in FHS were from plasma, which might not be accurate representations of the proteins expressed in platelets.
In this study, we combined pQTL data of 71 CVD-associated proteins, platelet measurements, and published platelet GWAS to identify 4 proteins causally associated with MPV and/or PLT. MPO was causally associated with MPV and three proteins (GP5, GRN, and MCAM) were causally associated with PLT in population genomics analyses. GP5 is a well-known receptor in platelets, but MCAM and GRN are not well-characterized platelet proteins. The results of iPSC-derived MK RNA-sequencing analysis were consistent with our population-based causal associations; GRN and GP5 were over-expressed, and MCAM down-regulated, respectively, in high-platelet producing clones. Gene knockdown experiments confirmed the causal associations for GP5 and GRN in addition to suggesting that MPO might also be causally implicated in platelet production. In total, the results suggest that these proteins are causally linked to platelet generation or turnover and may play important roles in CVD via a platelet-based mechanism. Additional research on these proteins such as functional studies using mice or zebrafish may elucidate specific mechanisms through which those proteins contribute to platelet counts, potentially identifying a platelet-mediated pathway from these proteins to CVD. *Effect allele and effect allele frequency (EAF) values were determined using the protein GWAS **Only BF significant cis-pQTLs (P < 1.25E-07) and trans-pQTLs (P < 7.04E-10) were considered for overlap analysis 
